Pharmacokinetics and pharmacodynamics - Is there anything new?

Anaesthesia

Volumn 67, Issue 1, 2012, Pages 5-11

  Rigby Jones, A E ^a   Sneyd, J R ^a  

^a PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROPOFOL;

ALLOMETRY; BLOOD SAMPLING; COMPUTER AIDED DESIGN; DRUG ADMINISTRATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE; DRUG EFFECT; DRUG HALF LIFE; MATHEMATICAL MODEL; PHARMACODYNAMICS; PHARMACOKINETICS; PROFESSIONAL PRACTICE; REVIEW; SAMPLING ERROR;

ALGORITHMS; ANESTHESIA; ANESTHETICS; BODY FLUID COMPARTMENTS; BODY WEIGHT; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MODELS, STATISTICAL; PHARMACOKINETICS; POPULATION;

EID: 83455210295     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2011.06993.x     Document Type: Review

References (35)

1. Hull CJ,. Pharmacokinetics and pharmacodynamics. British Journal of Anaesthesia 1979; 51: 579-94. (Pubitemid 10247938)
2. Shafer SL, Varvel JR,. Pharmacokinetics, pharmacodynamics, and rational opioid selection. Anesthesiology 1991; 74: 53-63.
3. Hughes MA, Glass PS, Jacobs JR,. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 1992; 76: 334-41.
4. Bailey JM,. Technique for quantifying the duration of intravenous anesthetic effect. Anesthesiology 1995; 83: 1095-103.
5. Minto CF, Schnider TW, Gregg KM, Henthorn TK, Shafer SL,. Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics. Anesthesiology 2003; 99: 324-33. (Pubitemid 36909558)
6. Wright PM,. Population based pharmacokinetic analysis: why do we need it; what is it; and what has it told us about anaesthetics? British Journal of Anaesthesia 1998; 80: 488-501. (Pubitemid 28171377)
7. Ogungbenro K, Aarons L,. An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments. Journal of Biopharmaceutical Statistics 2009; 19: 174-89.
8. Gabrielsson J, Weiner D,. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, 2nd edn. Stockholm: The Swedish Pharmaceutical Press, 1997.
9. Green B, Duffull SB,. Prospective evaluation of a D-optimal designed population pharmacokinetic study. Journal of Pharmacokinetics and Pharmacodynamics 2003; 30: 145-61. (Pubitemid 36886574)
10. Kleiber M,. Body size and metabolism. Hilgardia 1932; 6: 315-33.
11. Anderson BJ, Holford NH,. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metabolism and Pharmacokinetics 2009; 24: 25-36.
12. Anderson BJ, Holford NH,. Mechanism-based concepts of size and maturity in pharmacokinetics. Annual Review of Pharmacology and Toxicology 2008; 48: 303-32. (Pubitemid 351738156)
13. Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NH,. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. British Journal of Anaesthesia 2004; 92: 208-17. (Pubitemid 38159658)
14. Rigby-Jones AE, Priston MJ, Sneyd JR, et al., Remifentanil-midazolam sedation for paediatric patients receiving mechanical ventilation after cardiac surgery. British Journal of Anaesthesia 2007; 99: 252-61. (Pubitemid 47249397)
15. Marsh B, White M, Morton N, Kenny GN,. Pharmacokinetic model driven infusion of propofol in children. British Journal of Anaesthesia 1991; 67: 41-8.
16. Schnider TW, Minto CF, Gambus PL, et al., The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology 1998; 88: 1170-82. (Pubitemid 28216859)
17. Absalom AR, Mani V, De Smet T, Struys MM,. Pharmacokinetic models for propofol - defining and illuminating the devil in the detail. British Journal of Anaesthesia 2009; 103: 26-37.
18. Ingrande J, Brodsky JB, Lemmens HJ,. Lean body weight scalar for the anesthetic induction dose of propofol in morbidly obese subjects. Anesthesia and Analgesia 2011; 113: 57-62.
19. Servin F, Farinotti R, Haberer JP, Desmonts JM,. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. Anesthesiology 1993; 78: 657-65. (Pubitemid 23110039)
20. Cortinez LI, Anderson BJ, Penna A, et al., Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. British Journal of Anaesthesia 2010; 105: 448-56.
21. World Society of Intravenous Anaesthesia. The WorldSIVA Open TCI Initiative, 2011. (accessed 27/10/2011).
22. Krejcie TC, Avram MJ,. What determines anesthetic induction dose? It's the front-end kinetics, doctor! Anesthesia and Analgesia 1999; 89: 541-4. (Pubitemid 29409794)
23. Savic RM, Jonker DM, Kerbusch T, Karlsson MO,. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. Journal of Pharmacokinetics and Pharmacodynamics 2007; 34: 711-26. (Pubitemid 47477040)
24. Masui K, Kira M, Kazama T, Hagihira S, Mortier EP, Struys MM,. Early phase pharmacokinetics but not pharmacodynamics are influenced by propofol infusion rate. Anesthesiology 2009; 111: 805-17.
25. Upton RN, Ludbrook GL, Grant C, Martinez AM,. Cardiac output is a determinant of the initial concentrations of propofol after short-infusion administration. Anesthesia and Analgesia 1999; 89: 545-52. (Pubitemid 29409795)
26. Upton RN,. The two-compartment recirculatory pharmacokinetic model - an introduction to recirculatory pharmacokinetic concepts. British Journal of Anaesthesia 2004; 92: 475-84. (Pubitemid 38443847)
27. Fisher DM, Wright PM,. Are plasma concentration values necessary for pharmacodynamic modeling of muscle relaxants? Anesthesiology 1997; 86: 567-75. (Pubitemid 27118339)
28. Hahn JO, Khosravi S, Dumont GA, Ansermino JM,. Two-stage vs mixed-effect approach to pharmacodynamic modeling of propofol in children using state entropy. Pediatric Anesthesia 2011; 21: 691-8.
29. Jeleazcov C, Ihmsen H, Schmidt J, et al., Pharmacodynamic modelling of the bispectral index response to propofol-based anaesthesia during general surgery in children. British Journal of Anaesthesia 2008; 100: 509-16. (Pubitemid 351773602)
30. Rigouzzo A, Servin F, Constant I,. Pharmacokinetic-pharmacodynamic modeling of propofol in children. Anesthesiology 2010; 113: 343-52.
31. Glen JB, Servin F,. Evaluation of the predictive performance of four pharmacokinetic models for propofol. British Journal of Anaesthesia 2009; 102: 626-32.
32. Coppens MJ, Eleveld DJ, Proost JH, et al., An evaluation of using population pharmacokinetic models to estimate pharmacodynamic parameters for propofol and bispectral index in children. Anesthesiology 2011; 115: 83-93.
33. Ploeger BA, Smeets J, Strougo A, et al., Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex. Anesthesiology 2009; 110: 95-105.
34. Scott JC, Stanski DR,. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. Journal of Pharmacology and Experimental Therapeutics 1987; 240: 159-66. (Pubitemid 17235434)
35. Minto CF, Schnider TW, Egan TD, et al., Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology 1997; 86: 10-23. (Pubitemid 27043998)